Gallium-based anti-infectives: Targeting microbial iron-uptake mechanisms

Current Opinion in Pharmacology

Volumn 13, Issue 5, 2013, Pages 707-716

  Kelson, Andrew B ^a   Carnevali, Maia ^a   Truong Le, Vu ^a  

^a Aridis Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDROXYBENZOYLSERINE; ANTIINFECTIVE AGENT; CEPACIACHELIN; DEFEROXAMINE; DEUTEROPORPHYRIN GALLIUM; ENTEROCHELIN; FERRICHROME; GALLIUM; GALLIUM CHLORIDE; GALLIUM CITRATE; GALLIUM NITRATE; GENTAMICIN; HEMATOPORPHYRIN GALLIUM; HEME; LIPOSOME; MESOPORPHYRIN; MESOPORPHYRIN GALLIUM; METALLOPORPHYRIN; OCTAETHYLPORPHYRIN GALLIUM; PORPHINE GALLIUM; PROTOPORPHYRIN; PROTOPORPHYRIN GALLIUM; SIDEROPHORE; STAPHYLOFERRIN A; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM; BIOFILM; COMPLEX FORMATION; CYSTIC FIBROSIS; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IRON TRANSPORT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; GALLIUM; HEME; HUMANS; IRON; SIDEROPHORES;

EID: 84892973953     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.07.001     Document Type: Review

References (105)

1. Apseloff G: Therapeutic uses of gallium nitrate: past, present and future. Am J Ther 1999, 6: 327-339.
2. Collery P, Keppler B, Madoulet C, Desoize B: Gallium in cancer treatment. Crit Rev Oncol Hematol 2002, 42: 283-296. (Pubitemid 34615690)
3. Bernstein LR: Mechanisms of therapeutic activity for gallium. Pharmacol Rev 1998, 50: 665-682. (Pubitemid 29028814)
4. Chitambar CR: Medical applications and toxicities of gallium compounds. Int J Environ Res Public Health 2010, 7: 2337-2361.
5. Olakanmi O, Britigan BE, Schlesinger LS: Gallium disrupts iron metabolism of mycobacteria residing within human macrophages. Infect Immun 2000, 68: 5619-5627.
6. Warrell RP Jr, Lovett D, Dilmanian FA, Schneider R, Heelan RT: Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol 1993, 11: 2443-2450. (Pubitemid 23353976)
7. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock REW, Martinez JL: The intrinsic resistome of Pseudomonas aeruginosa to b-lactams. Virulence 2011, 2: 144-146.
8. Santos Costa S, Viveiros M, Amaral L, Couto I: Multidrug efflux pumps in Staphylococcus aureus: an update. Open Microbiol J 2013, 7(Suppl. 1): 59-71.
9. Skaar EP: The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathog 2010, 6: 1-4.
10. Pattus F, Abdallah MA: Siderophores and iron-transport in microorganisms. J Chin Chem Soc 2000, 47: 1-20.
11. Ferguson AD, Deisenhofer J: TonB-dependent receptors- structural perspectives. Biochim Biophys Acta 2002, 1565: 318-332.
12. Chitambar CR, Narasimhan J: Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology 1991, 59: 3-10.
13. Kaneko Y, Thoendel M, Olakanmi O, Britigan BE, Singh PK: The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 2007, 117: 877-888. (Pubitemid 46556744)
14. DeLeon K, Balldin F, Watters C, Hamood A, Griswold J, Sreedharan S, Rumbaugh KP: Gallium maltolate treatment eradicates Pseudomonas aeruginosa infection in thermally injured mice. Antimicrob Agents Chemother 2009, 53: 1331-1337.
15. Griffiths E: Iron in biological systems. In Iron and Infection: Molecular, Physiological and Clinical Aspects, 2nd ed. Edited by Bullen DJ, Griffiths E.Chichester: John Wiley & Sons Ltd.; 1999: 1-26.
16. Rodriguez GM, Gardner R, Kaur N, Phanstiel O IV: Utilization of Fe3+-acinetoferrin analogs as an iron source by Mycobacterium tuberculosis. Biometals 2008, 21: 93-103. (Pubitemid 351170145)
17. Stojiljkovic I, Kumar V, Srinivasan N: Non-iron metalloporphryrins: potent antibacterial compounds that exploit haem/Hb uptake systems of pathogenic bacteria. Mol Microbiol 1999, 31: 429-442. (Pubitemid 29046086)
18. Stojiljkovic I, Evavold BD, Kumar V: Antimicrobial properties of porphyrins. Expert Opin Invest Drugs 2001, 10: 309-320. (Pubitemid 32117939)
19. Chenier D, Beriault R, Mailloux R, Baquie M, Abramia JL, Appanna V: Involvement of fumarase C and NADH oxidase in metabolic adaptation of Pseudomonas fluorescens cells evoked by aluminum and gallium toxicity. Appl Environ Microbiol 2008, 74: 3977-3984. (Pubitemid 351962422)
20. Rzhepishevska O, Ekstran-Hammarstrom B, Popp M, Bjorn E, Bucht A, Sjostedt A, Antii H, Ramstedt M: The antibacterial activity of Ga3+ is influenced by ligand complexation as well as the bacterial carbon source. Antimicrob Agents Chemother 2011, 55: 5568-5580.
21. Kvitko BH, Goodyear A, Propst KL, Dow SW, Schweizer HP: Burkholderia pseudomallei known siderophores and hemin uptake are dispensable for lethal murine Melioidosis. PLoS Negl Trop Dis 2012, 6: 1-13.
22. Tong Y, Guo M: Bacterial heme-transport proteins and their heme-coordination modes. Arch Biochem Biophys 2009, 481: 1-15.
23. Beasley FC, Heinrichs DE: Siderophore-mediated iron acquisition in the staphylococci. J Inorg Biochem 2010, 104: 282-288.
24. Krieg S, Huche F, Diederichs K, Izadi-Pruneyred N, Lecroisey A, Wandersman C, Delepelaire P, Welte W: Heme uptake across the outer membrane as revealed by crystal structures of the receptor-hemophore complex. Proc Natl Acad Sci 2009, 106: 1045-1050.
25. Moriwaki Y, Caaveiro JM, Tanaka Y, Tsutsumi H, Hamachi I, Tsumoto K: Molecular basis of recognition of antibacterial porphyrins by heme-transporter IsdH-NEAT3 of Staphylococcus aureus. Biochemistry 2011, 50: 7311-7320.
26. Chopra I, Roberts M: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001, 65: 232-260. (Pubitemid 32538179)
27. Mukhtar TA, Wright GD: Streptogramins, oxazolidones and other inhibitors of bacterial protein synthesis. Chem Rev 2005, 105: 529-542. (Pubitemid 40351632)
28. Kattan JN, Villegas MV, Quinn JP: New developments in carbapenems. Clin Microbiol Infect 2008, 14: 1102-1111.
29. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA: Comparative review of the carbapenems. Drugs 2007, 67: 1027-1052. (Pubitemid 46744477)
30. Levine DP: Vancomycin: a history. Clin Infect Dis 2006, 42(Suppl. 1): 5-12.
31. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R: Spectrum and mode of action of Azithromycin (CP-62,993), a new 15-membered- ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1978, 31: 1939-1947.
32. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K: In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother 2010, 54: 1955-1964.
33. Proschak A, Lubuta P, Grun P, Lohr F, Wilharm G, De Berardinis V, Bode HB: Structure and biosynthesis of Fimsbactins A-F, siderophores from Acinetobacter baumannii and Acinetobacter baylyi. Chem Biol Chem 2013, 14: 633-638.
34. Nielsen A, Mansson M, Wietz M, Varming AN, Phipps RK, Larsen TO, Gram L, Ingmer H: Nigribactin, a novel siderophore from Vibrio nigripulchritudo, modulates Staphylococcus aureus virulence gene expression. Mar Drugs 2012, 10: 2584-2595.
35. Wandersman C, Delepelaire P: Bacterial iron sources: from siderophores to hemophores. Annu Rev Microbiol 2004, 58: 611-647. (Pubitemid 39551999)
36. Crosa JH, Walsh CT: Genetics and assembly line enzymology of siderophore biosynthesis in bacteria. Microbiol Mol Biol Rev 2002, 66: 223-249. (Pubitemid 34625709)
37. Goetz DH, Holms MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002, 10: 1033-1043. (Pubitemid 36001971)
38. Fardeau S, Mullie C, Dassonville-Klimpt A, Audic N, Sasaki A, Sonnet P: Bacterial iron uptake: a promising solution against multidrug resistant bacteria. In Science Against Microbial Pathogens: Communicating Current Research and Technological Advances, vol 2. Edited by Mendez-Vilas A. 2011: 695-705.
39. Miethke M, Maraheil MA: Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 2007, 71: 413-451. (Pubitemid 47429279)
40. Raymond KN, Dertz EA, Kim SS: Enterobactin: an archetype for microbial iron transport. Proc Natl Acad Sci 2003, 100: 3584-3588. (Pubitemid 36418077)
41. Hotta K, Kim C-Y, Fox DT, Koppisch AT: Siderophore-mediated iron acquisition in Bacillus anthracis and related strains. Microbiology 2010, 156: 1918-1925.
42. Agnoli K, Lowe CA, Farmer KL, Husnain SI, Thomas MS: The ornibactin biosynthesis and transport genes of Burkholderia cenocepacia are regulated by an extracytoplasmic function s factor which is a part of the Fur regulon. J Bacteriol 2006, 188: 3631-3644. (Pubitemid 43726227)
43. Stinzi A, Barnes C, Xu J, Raymond KN: Microbial iron transport via a siderophore shuttle: a membrane iron transport paradigm. Proc Natl Acad Sci 2000, 97: 10691-10696.
44. Konetschny-Rapp S, Jung G, Meiwes J, Zahner H: Staphyloferrin A: a structurally new siderophore from Staphylococci. Eur J Biochem 1990, 191: 65-74. (Pubitemid 20219031)
45. Raymond KN: Recognition and transport of natural and synthetic siderophores by microbes. Pure Appl Chem 1994, 66: 773-781.
46. Fadeev EA, Luo M, Groves JT: Synthesis and structural modeling of the amphiphilic siderophore rhizobactin-1021 and its analogs. BioOrg Med Chem Lett 2005, 15: 3771-3774. (Pubitemid 41038976)
47. Juárez-Hernández RE, Franzblau SG, Miller MJ: Synthesis of mycobactin analogs as potent and selective inhibitors of Mycobacterium tuberculosis. Org Biomol Chem 2012, 19: 7584-7593.
48. Lamont IL, Martin LW: Identification and characterization of novel pyoverdine synthesis genes in Pseudomonas aeruginosa. Microbiology 2003, 149: 833-842. (Pubitemid 36553353)
49. Snow GA: Mycobactins: iron-chelating growth factors from Mycobacteria. Bacteriol Rev 1970, 34: 99-125.
50. Meyer JM, Neely A, Stintzi A, Georges C, Holder IA: Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect Immun 1996, 64: 518-523. (Pubitemid 26032823)
51. Marshall B, Stinzi A, Gilmour C, Meyer J-M, Poole K: Citrate-mediated iron uptake in Pseudomonas aeruginosa: involvement of the citrate-inducible FecA receptor and the FeoB ferrous iron transporter. Microbiology 2009, 155: 305-315.
52. Youard ZA, Reimmann C: Stereospecific recognition of pyochelin and enantio-pyochelin by the PchR proteins in fluorescent pseudomonads. Microbiology 2010, 156: 1772-1782.
53. Zimbler DL, Penwell WF, Gaddy JA, Menke SM, Tomaras AP, Connerly PL, Actis LA: Iron acquisition functions expressed by the human pathogen Acinetobacter baumannii. Biometals 2009, 22: 23-32.
54. Dorsey CW, Tomaras AP, Connerly PL, Tolmasky ME, Crosa JH, Actis LA: The siderophore-mediated iron acquisition systems of Acinetobacter baumannii ATCC 19606 and Vibrio anguillarum 775 are structurally and functionally related. Microbiology 2004, 150: 3657-3667. (Pubitemid 39545313)
55. Bachman MA, Lenio S, Schmidt L, Oyler JE, Welser JN: Interaction of liopcalin 2, transferrin and siderophores determines the replicative niche of Klebsiella pneumonia during pneumonia. mBio 2012, 3: 1-8.
56. Perry RD, San Clemente CL: Siderophore synthesis in Klebsiella pneumonia and Shigella sonnei during iron deficiency. J Bacteriol 1979, 140: 1129-1132. (Pubitemid 10177692)
57. Sobczak I, Lolkema JS: Loop VIII/IX of the Na+-citrate transporter CitS of Klebsiella pneumonia folds into an amphipathic surface helix. Biochemistry 2005, 44: 5461-5470. (Pubitemid 40489985)
58. Thomas MS: Iron acquisition mechanism of the Burkholderia cepacia complex. Biometals 2007, 20: 431-452. (Pubitemid 46776579)
59. Mislin GLA, Hoegy F, Cobessi D, Poole K, Rognan D, Schalk IJ: Binding properties of pyochelin and structurally related molecules to FptA of Pseudomonas aeruginosa. J Mol Biol 2006, 357: 1437-1448.
60. LétofféS, Heuck G, Delepelaire P, Lange N, Wandersman C: Bacteria capture iron from heme by keeping tetrapyrrol skeleton intact. Proc Natl Am Soc 2009, 106: 11719-11724.
61. Payne SM, Niesel DW, Peixotto SS, Lawlor KM: Expression of hydroxamate and phenolate siderophores by Shigella flexneri. J Bacteriol 1983, 155: 949-955. (Pubitemid 13023061)
62. Mills M, Payne SM: Genetics and regulation of heme iron transport in Shigella dysenteriae and detection of an analogous system in Escherichia coli O127:H7. J Bacteriol 1995, 177: 3004-3009.
63. Tai SS, Lee C-J, Winter RE: Hemin utilization is related to virulence of Streptococcus pneumonia. Infect Immun 1993, 61: 5401-5405. (Pubitemid 23353928)
64. Simon N, Coulanges V, Andre P, Vidon DJ-M: Utilization of exogenous siderophores and natural catechols by Listeria monocytogenes. Appl Environ Microbiol 1995, 61: 1643-1645.
65. Rossi M-S, Fetherston JD, LétofféS, Carniel E, Perry RD, Ghigo J-M: Identification and characterization of the hemophore- dependent heme acquisition system of Yersinia pestis. Infect Immun 2001, 69: 6707-6717. (Pubitemid 32995428)
66. Perry RD, Balbo PB, Jones HA, Fetherston JD, DeMoll E: Yersiniabactin pestis: biochemical characterization of the siderophore and its role in iron transport. Microbiology 1999, 145: 1181-1190. (Pubitemid 29231822)
67. Anzaldi LL, Skaar EP, Minireview: Overcoming the heme paradox: heme toxicity and tolerance in bacterial pathogens. Infect Immun 2010, 78: 4977-4989.
68. Cescau S, Cwerman H, LétofféS, Delepelaire P, Wandersman C, Biville F: Heme acquisition by hemophores. Biometals 2007, 20: 603-613. (Pubitemid 46776565)
69. Wilks A, Burkhard KA: Heme and virulence: how bacterial pathogens regulate, transport and utilize heme. Nat Prod Rep 2007, 24: 511-522. (Pubitemid 46848712)
70. Koster W: ABC transporter mediated uptake of iron, siderophores, heme and vitamin B12. Res Microbiol 2001, 152: 291-301. (Pubitemid 32436487)
71. Reniere ML, Torres VJ, Skaar EP: Intracellular metalloporphyrin metabolism in Staphylococcus aureus. Biometals 2007, 20: 333-345. (Pubitemid 46776560)
72. Skaar EP, Humayun M, Bae T, DeBord KL, Schneewind O: Iron-source preference of Staphylococcus aureus infections. Science 2004, 305: 1626-1628. (Pubitemid 39296358)
73. Braun V, Braun M: Active transport of iron and siderophore antibiotics. Curr Opin Microbiol 2002, 5: 194-201. (Pubitemid 34289928)
74. Hammer ND, Skaar EP: Molecular mechanisms of Staphylococcus aureus iron acquisition. Annu Rev Microbiol 2011, 65: 129-147.
75. Ratledge C, Dover LG: Iron metabolism in pathogenic bacteria. Annu Rev Microbiol 2000, 54: 881-941.
76. Schlesinger LS, Britigan BE: Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection, US Patent 6203822, 1996.
77. Kelsen DP, Alcock N, Yeh S, Brown J, Young C: Pharmacokinetics of gallium nitrate in man. Cancer 1980, 46: 2009-2013. (Pubitemid 10025477)
78. Harris WR, Messori L: A comparative study of aluminum(III):gallium(III): indium(III) and thallium(III) binding to human serum transferrin. Coord Chem Rev 2002, 228: 237-262.
79. Clarke TE, Tari LW, Vogel HJ: Structural biology of bacterial uptake systems. Curr Top Med Chem 2001, 1: 7-30.
80. Halwani M, Yebio B, Suntres ZE, Alipour M, Azghani AO, Omri A: Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J Antimicrob Chemother 2008, 62: 1291-1297.
81. Staff K, Brown MB, Hider RC, Kong XL, Friden P, Jones SA: Recovering Ga(III) from coordination complexes using pyridine 2,6-dicarboxylic acid chelation ion chromatography. Biomed Chromatogr 2010, 24: 1015-1022.
82. Bernstein LR, Tanner T, Godfrey C, Noll B: Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Met-Based Drugs 2000, 7: 33-47. (Pubitemid 30153561)
83. Martens RD, Miller NA, Cohen ND, Harrington JR, Bernstein LR: Chemoprophylactic antimicrobial activity of gallium maltolate against intracellular Rhodococcus equi. J Equine Vet Sci 2007, 27: 341-345. (Pubitemid 47212632)
84. Lechuga-Ballesteros D, Kakiuchi T, Pham B, Patzer EJ, Truong V: Suppl 31, Abstract # 263. North American Cystic Fibrosis Conference; Orlando, FL, October: 2008.
85. Goss CH, Hornick DB, Aitken ML, Wolfstone AE, Caldwell E, Wilhelm DE, Genatossio A, Teresi M, Singh PK: Abstract #273. 25th North America Cystic Fibrosis Conference; Anaheim, CA, November: 2011.
86. Goss CH, Hornick DB, Aitken ML, Wolfstone AE, Caldwell E, Wilhelm DE, Wilhelm A, Teresi M, Singh PK: Abstract #S13.3. 26th North America Cystic Fibrosis Conference; Orlando, FL, October: 2012.
87. Ancliff RA, Russell AT, Sanderson AJ: Resolution of a citric acid derivative: synthesis of (R)-(S)-homocitric acid-g-lactone. Tetrahedron: Asymmetry 1997, 8: 3379-3382. (Pubitemid 27465885)
88. Xin MG: PhD Thesis. University of Florida; 2000.
89. Gardner RA, Kinkade R, Wang C, Phanstiel O IV: Total synthesis of petrobactin and its homologues as potential stimuli for Marinobacter hydrocarbonoclasiticus, an oil-degrading bacteria. J Org Chem 2004, 69: 3530-3537. (Pubitemid 38621303)
90. Dinello RR, Chang CK: In The Porphyrins, vol 1. Edited by Dolphin D. New York: Academic Press; 1978:289.
91. Morgan B, Dolphin D: Synthesis and structure of biomimetic porphyrin. In Structure and Bonding, 64. Edited by Buchler J. Springer-Verlag; 1987: 115-203.
92. Shanmugathasan S, Edwards C, Boyle RW: Advances in modern synthetic porphyrin chemistry. Tetrahedron 2000, 56: 1025-1046. (Pubitemid 30104440)
93. Josefson LB, Boyle RW: Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photo dynamic therapy, imaging and theranostics. Theranostics 2012, 2: 916-966.
94. Bhaumik J: PhD Thesis. North Carolina State University; 2007.
95. Hargus JA: MSc Thesis. Louisiana State University; 2001.
96. Ballouche M, Cornelis P, Baysse C: Iron metabolism: a promising target for antibacterial strategies. Recent Pat Antiinfect Drug Discov 2009, 4: 190-205.
97. Olczak T, Maszczak-Seneczko D, Smalley JW, Olczak M: Gallium(III), cobalt(III) and copper(II) protoporphyrin IX exhibit antimicrobial activity against Porphyromonas gingivalis by reducing planktonic and biofilm growth and invasion of host epithelial cells. Arch Microbiol 2012, 194: 719-724.
98. Stojiljkovic I, Churchward G: Non-iron metalloporphyrins and methods of use, US Patent # 6066628, 2000.
99. Cannon JB: Pharmaceutics and drug delivery aspects of heme and porphyrin therapy. J Pharm Sci 1993, 82: 435-446. (Pubitemid 23150443)
100. Banin E, Lozinski A, Brady KM, Berenshtein E, Butterfield PW, Moshe M, Chevion M, Greenberg EP, Banin E: The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent. Proc Natl Acad Sci 2008, 105: 16671-16766.
101. Coutsolelos A, Guilard R: Synthese et characteristiques physicochimiques de gallioporphyrines a liaisons metal-carbone. J Organomet Chem 1983, 253: 273-281.
102. Wong CP, Venteicher RF, Horrocks WD Jr: Lanthanide porphyrin complexes: a potential new class of nuclear magnetic resonance dipole probe. J Am Chem Soc 1974, 96: 7149-7150.
103. Macquet JP, Theophanides T: Complexes d'hematoporphyrine IX avec le platine (II): synthese, intermediaires, spectres, interet biologique. Can J Chem 1973, 51:219.
104. Wijesekera TP, Dolphin D: Synthetic aspects of porphyrin and metalloporphyrin chemistry. In Metalloporphyrins in Catalytic Oxidations. Edited by Sheldon RA. NY: Marcel Dekker Inc.; 1994: 193-239. (Chapter 7).
105. Bohle DS, Dodd EL, Pinter TBJ, Stillman MJ: Soluble diamagnetic model for Malaria pigment: coordination chemistry of gallium(III)protoporphyrin-IX. Inorg Chem 2012, 51:10747-10761